W Budzyński

463 total citations
24 papers, 394 citations indexed

About

W Budzyński is a scholar working on Immunology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, W Budzyński has authored 24 papers receiving a total of 394 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 10 papers in Molecular Biology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in W Budzyński's work include Immunotherapy and Immune Responses (5 papers), Glycosylation and Glycoproteins Research (4 papers) and Immune Cell Function and Interaction (4 papers). W Budzyński is often cited by papers focused on Immunotherapy and Immune Responses (5 papers), Glycosylation and Glycoproteins Research (4 papers) and Immune Cell Function and Interaction (4 papers). W Budzyński collaborates with scholars based in United States, Poland and Canada. W Budzyński's co-authors include C Radzikowski, R. Rao Koganty, Mark J. Krantz, B. Michael Longenecker, Mark A. Reddish, John Samuel, Zi‐Hua Jiang, James A. Rogers, Lei Ding and Dongxu Qiu and has published in prestigious journals such as International Journal of Cancer, Tetrahedron and Journal of Immunological Methods.

In The Last Decade

W Budzyński

23 papers receiving 381 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W Budzyński United States 10 239 200 76 53 44 24 394
M Berger Austria 9 267 1.1× 220 1.1× 169 2.2× 49 0.9× 37 0.8× 13 480
E Wolff Germany 12 102 0.4× 192 1.0× 74 1.0× 86 1.6× 40 0.9× 17 398
Neeraja Dharmaraj United States 14 314 1.3× 258 1.3× 137 1.8× 66 1.2× 23 0.5× 20 604
Jennifer Patterson United States 13 160 0.7× 310 1.6× 60 0.8× 38 0.7× 69 1.6× 27 648
Richard W. Roof United States 8 352 1.5× 273 1.4× 38 0.5× 111 2.1× 54 1.2× 9 589
S. Mouritsen Denmark 13 304 1.3× 256 1.3× 55 0.7× 181 3.4× 39 0.9× 21 547
Marjorie H. Middleton United States 10 308 1.3× 160 0.8× 37 0.5× 137 2.6× 71 1.6× 15 608
Isis Torréns Cuba 11 147 0.6× 225 1.1× 45 0.6× 45 0.8× 63 1.4× 21 377
Franz Kricek Austria 17 242 1.0× 152 0.8× 48 0.6× 187 3.5× 23 0.5× 38 645
Melina Soares United States 5 249 1.0× 205 1.0× 54 0.7× 71 1.3× 41 0.9× 11 418

Countries citing papers authored by W Budzyński

Since Specialization
Citations

This map shows the geographic impact of W Budzyński's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W Budzyński with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W Budzyński more than expected).

Fields of papers citing papers by W Budzyński

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W Budzyński. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W Budzyński. The network helps show where W Budzyński may publish in the future.

Co-authorship network of co-authors of W Budzyński

This figure shows the co-authorship network connecting the top 25 collaborators of W Budzyński. A scholar is included among the top collaborators of W Budzyński based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W Budzyński. W Budzyński is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rzechonek, Adam, et al.. (2016). Limited Clinical Significance of Dimeric Form of Pyruvate Kinase as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Cancer. Advances in experimental medicine and biology. 955. 51–57. 6 indexed citations
2.
Alviar, Carlos L., Armando Téllez, Michael Wang, et al.. (2012). Low-dose sirolimus-eluting hydroxyapatite coating on stents does not increase platelet activation and adhesion ex vivo. Journal of Thrombosis and Thrombolysis. 34(1). 91–98. 11 indexed citations
3.
Jiang, Zi‐Hua, W Budzyński, Dongxu Qiu, Yalamati Damayanthi, & R. Rao Koganty. (2007). Monophosphoryl lipid A analogues with varying 3-O-substitution: synthesis and potent adjuvant activity. Carbohydrate Research. 342(6). 784–796. 33 indexed citations
4.
Das, Dipankar, et al.. (2005). Antigen targeting to dendritic cells with bispecific antibodies. Journal of Immunological Methods. 306(1-2). 80–92. 9 indexed citations
5.
Budzyński, W, et al.. (2002). Lipid A structures containing novel lipid moieties: synthesis and adjuvant properties. Bioorganic & Medicinal Chemistry Letters. 12(16). 2193–2196. 25 indexed citations
6.
Jiang, Zi‐Hua, et al.. (2002). Novel lipid A mimetics derived from pentaerythritol: synthesis and their potent agonistic activity. Tetrahedron. 58(43). 8833–8842. 24 indexed citations
7.
Samuel, John, W Budzyński, Mark A. Reddish, et al.. (1998). Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. International Journal of Cancer. 75(2). 295–302. 69 indexed citations
8.
Budzyński, W, R. Rao Koganty, Mark J. Krantz, et al.. (1998). Liposomal Formulations of Synthetic MUC1 Peptides:  Effects of Encapsulation versus Surface Display of Peptides on Immune Responses. Bioconjugate Chemistry. 9(4). 451–458. 80 indexed citations
9.
Radzikowski, C, et al.. (1996). Cytotoxicity and proliferation of splenocytes and lymph node cells from adjuvant‐treated nude mice:. Apmis. 104(7-8). 647–658. 1 indexed citations
10.
Budzyński, W & C Radzikowski. (1994). Cytotoxic Cs in Immunodeficient Athymic Mice. Immunopharmacology and Immunotoxicology. 16(3). 319–346. 70 indexed citations
11.
Budzyński, W, et al.. (1992). Activity of natural killer (NK) cells in the course of experimental trichinellosis in mice.. PubMed. 38(3-4). 117–26. 6 indexed citations
12.
Schlick, E., et al.. (1987). Immune response by biological response modifiers.. PubMed. 1. 385–97. 1 indexed citations
13.
Budzyński, W, Michael A. Chirigos, & Eilene Gruys. (1987). Augmentation of natural cell activity in tumor-bearing and normal mice by MVE-2. Cancer Immunology Immunotherapy. 24(3). 253–8. 8 indexed citations
14.
Ruffmann, R., et al.. (1987). Protein deficiency reduces natural antitumor immunity.. PubMed. 1. 15–27. 3 indexed citations
15.
Paprocka, Maria, et al.. (1986). Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. I. Antitumour effect of cyclophosphamide and ifosfamide enantiomers.. PubMed. 34(3). 275–84. 5 indexed citations
16.
Chirigos, M. A., et al.. (1985). Pharmacokinetic and therapeutic activity of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethylcellulose [poly(I,C)-LC].. PubMed. 4(6). 621–7. 3 indexed citations
17.
Budzyński, W. (1984). Changes in natural killer cells activity in mice bearing subcutaneously implanted Lewis lung carcinoma.. PubMed. 32(2). 185–9.
18.
Janiak, Marek K., W Budzyński, C Radzikowski, et al.. (1984). Stimulatory Effect of Propionibacterium Granulosum KP-45, Glucan and Pyran Copolymer on the Activity of Natural Killer (NK) Cells in Murine Lungs. Immunobiology. 167(4). 328–337. 9 indexed citations
19.
Budzyński, W. (1982). Lewis lung carcinoma in mice as an experimental therapy model. I. The growth kinetics and the effect of tumor on host.. PubMed. 30(5-6). 363–72. 4 indexed citations
20.
Radzikowski, C, et al.. (1982). Studies on antitumor and myelotoxic effect of Ledakrin and its selected analogues.. PubMed. 30(5-6). 385–93. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M Berger Breakdown of academic impact, for papers by E Wolff Breakdown of academic impact, for papers by Neeraja Dharmaraj Breakdown of academic impact, for papers by Jennifer Patterson Breakdown of academic impact, for papers by Richard W. Roof Breakdown of academic impact, for papers by S. Mouritsen Breakdown of academic impact, for papers by Marjorie H. Middleton Breakdown of academic impact, for papers by Isis Torréns Breakdown of academic impact, for papers by Franz Kricek Breakdown of academic impact, for papers by Melina Soares
Rankless by CCL
2026